P1185: A PROSPECTIVE SINGLE-CENTER PHASE 2 STUDY OF ZANUBRUTINIB PLUS R-CHOP IN TREAT-NAÏVE INTRAVASCULAR LARGE B CELL LYMPHOMA

作者：Yan Zhang, Chao Chen, Danqing Zhao, Zhe Zhuang, Chong Wei, Wei Wang, Wei Zhang, Daobin Zhou · 发表于：HemaSphere · 年份：2023 · DOI：10.1097/01.hs9.0000971636.16625.73 · 被引用次数：4 · 研究领域：CNS Lymphoma Diagnosis and Treatment、Chronic Lymphocytic Leukemia Research、Lymphoma Diagnosis and Treatment

Topic: 19. Aggressive Non-Hodgkin lymphoma - Clinical Background: Intravascular large B-cell lymphoma (IVLBCL) is a rare disease for which there is no available standard treatment. Zanubrutinib is a selective Bruton Tyrosine kinase(BTK) inhibitor and has shown activity in several B cell lymphomas. Aims: We aimed to ascertain the safety and activity of zanubrutinib plus R-CHOP (rituximab, cyclophosphamide, epirubicin, vindesine, and prednisolone) for patients with previously untreated IVLBCL Methods: This is a prospective, single-arm, phase 2 trial at Peking Union Medical College Hospital in China. Eligible patients had untreated histologically confirmed IVLBCL, were aged>18 years, had adequate bone marrow and organ function, had no active infections or bleeding. Patients received 8 cycles of zanubrutinib (160mg bid orally) plus R-CHOP (rituximab 375 mg/m² intravenously on day 1; cyclophosphamide 750 mg/m², epirubicin 70 mg/m², and vindesine 4mg intravenously on day 1 and prednisolone 100 mg orally on days 1–5) every 3 weeks. The primary endpoint was 2-year progression-free survival. Secondary end points included safety profile. The trial is registered at ClinicalTrials.gov (NCT 04899570) and is still recruiting. Results: By 14th February,2023, 23 patients were enrolled into the study, 13 patients had finished 8 cycles treatment, 9 were still under treatment and 1 withdrew due to adverse events. All 23 patients were Ann Arbor IVB stage (median age 59, 14 males), and in interme...